Your search returned 3 results.

Results
	1.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	2.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	3.	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. MedStar authors: Swain, Sandra M PMID: 27692565 Year: 2017 Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Gao JJ, Pohlmann PR, Swain SM, Tan M DOI: https://dx.doi.org/10.1016/j.clbc.2016.08.005 Add to cart (remove)

Powered by Koha